Salivary chemokine-binding protein which has chemokine-neutralizing activity and binds to host chemokines CCL1, CCL3, CCL5, CCL7, CCL8, CCL11, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL21, CCL22, CCL23, CCL24, CCL25 and CCL26 with nanomolar affinity (PubMed:18678732, PubMed:23910450, PubMed:25266725). Binds to CCL3 and CCL5 with 1:1 stoichiometry (PubMed:23910450). Although binding to CCL25 is observed, does not inhibit CCL25-induced chemotaxis (PubMed:25266725).Has been shown to reduce cardiac injury and inflammation in mice through its anti-CCL5 activity (PubMed:23925450). Monomer. N-terminus residues are involved in complex formation with CCL5. A N-terminal derivative peptide composed of residues 37-54 inhibits CCL5 activity in monocyte migration assays, suggesting that Evasin-4 derivatives could be used as a starting point for the development of anti-inflammatory drugs. Belongs to the evasin C8 family. Hidden powers - Issue 99 of November 2008